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BACKGROUND: Folate, vitamin B6 and vitamin B12 have been associated with digestive system cancers. We conducted a two-
sample Mendelian randomisation study to assess the causality of these associations.
METHODS: Two, one and 14 independent single nucleotide polymorphisms associated with serum folate, vitamin B6 and vitamin
B12 at the genome-wide significance threshold were selected as genetic instruments. Summary-level data for the associations of
the vitamin-associated genetic variants with cancer were obtained from the UK Biobank study including 367,561 individuals and
FinnGen consortium comprising up to 176,899 participants.
RESULTS: Genetically predicted folate and vitamin B6 concentrations were not associated with overall cancer, overall digestive
system cancer or oesophageal, gastric, colorectal or pancreatic cancer. Genetically predicted vitamin B12 concentrations were
positively associated with overall digestive system cancer (ORSD, 1.12; 95% CI 1.04, 1.21, p= 0.003) and colorectal cancer (ORSD 1.16;
95% CI 1.06, 1.26, p= 0.001) in UK Biobank. Results for colorectal cancer were consistent in FinnGen and the combined ORSD was
1.16 (95% CI 1.08, 1.25, p < 0.001). There was no association of genetically predicted vitamin B12 with any other site-specific
digestive system cancers or overall cancer.
CONCLUSIONS: These results provide evidence to suggest that elevated serum vitamin B12 concentrations are associated with
colorectal cancer.
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BACKGROUND
Folate, vitamin B6 and vitamin B12 have important roles in DNA
methylation, synthesis and repair and have been proposed to
modify the risk of cancer, in particular digestive system cancers.
Notwithstanding, the association between these B vitamins and
digestive system cancers is not fully understood. Findings on
folate in relation to risk of colorectal cancer are conflicting with
neutral,1 inverse2 and positive3 associations reported, whereas
folate intake appears to lower the risk of upper gastrointestinal
system cancers.4,5 Vitamin B6 and its principal active coenzyme
form (pyridoxal 5′-phosphate) were identified to be associated
with a reduced risk of all cancers and gastrointestinal cancers in a
systematic review and meta-analysis involving 121 observational
studies.6 Although randomised controlled trials (RCTs) have
revealed no association between supplementation of B vitamins
and overall cancer incidence, no trials to date have studied
cancer as the primary endpoint or with sufficient incident
cancers.6 Elevated plasma vitamin B12 concentrations have been
associated with an increased cancer incidence within the first
year of follow-up,7,8 but the long-term consequences of elevated
vitamin B12 concentrations on the risk of overall digestive
system cancer have been scarcely investigated and results are
conflicting.3,9–11
Multivitamins and B vitamin supplements are commonly used
in adults. Approximately 30–40% of U.S. adults take folate, vitamin
B6 or vitamin B12 supplements, and the percentages are even
higher among older Caucasian women.12 Meanwhile, cancer
projects a heavy burden on human health worldwide.13 Thus, it
is of great importance to understand the role of supplementation
of B vitamins on cancer development.
Mendelian randomisation (MR) analysis can strengthen the
causal inference in an exposure-outcome association by using
genetic variants as instruments for an exposure.14 The MR design
can minimise residual confounding and reverse causation biases.14
Here, we conducted an MR investigation to determine the
associations of genetically predicted circulating concentrations
of folate and of vitamins B6 and B12 concentrations with the risk
of overall and digestive system cancers. Folate and vitamin B12
deficiency is associated with pernicious anaemia and mean
corpuscular volume,15 which were used as positive control
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Three, one and 15 single nucleotide polymorphisms (SNPs)
associated with serum folate, vitamin B6 and vitamin B12 at the
genome-wide significance level (p < 5 × 10−8) were identified in
meta-analyses of genome-wide association studies (GWASs) on
folate (37,341 individuals of European ancestries),16 vitamin B6
(1864 individuals of European descent),17 and vitamin B12 (45,576
individuals of European ancestries).16 The average concentrations
of B vitamins in these GWASs were ~20.0 nmol/L for folate, 9.4 ng/
mL for vitamin B6 and 391.0 pmol/L for vitamin B12. The SNPs
explained ~1.0%, 2.8% and 6.3% phenotypic variance for folate,
vitamin B6 and vitamin B12, respectively. Linkage disequilibrium
among SNPs for folate and vitamin B12 was estimated based on
the 1000 Genomes European panel and SNPs with linkage
disequilibrium (r2 > 0.01 or clumping distance>10 kb) were
removed, leaving two and 14 SNPs as instrumental variables for
serum folate and vitamin B12, respectively.
Cancer data sources
We obtained summary-level data (beta coefficients and corre-
sponding standard errors) for the associations of the B vitamin-
associated SNPs with cancer from the UK Biobank study18 and the
FinnGen consortium.19 In UK Biobank, there were 90,363 cases for
overall cancer, 11,061 cases for digestive system cancer (including
oesophageal, gastric, pancreatic, hepatocellular, biliary tract and
colorectal cancers), 1228 cases for oesophageal cancer, 994 cases
for gastric cancer, 6995 cases for colorectal cancer and 1747 cases
for pancreatic cancer and up to 307,914 non-cancer cases. The
FinnGen ascertained 29,617 cases for overall cancer, 4298 cases
for digestive system cancer (similarly defined in UK Biobank), 193
cases for oesophageal cancer, 506 cases for gastric cancer, 2435
cases for colorectal cancer and 519 cases for pancreatic cancer
and 147,282 non-cancer cases. Data sources descriptions, diag-
nostic information and used data are presented in Supplementary
Methods and Supplementary Tables 1–3.
Statistical analysis
The inverse-variance weighted method under a multiplicative
random-effects model was employed as the primary statistical
method.20 Estimates from UK Biobank and FinnGen were
combined using fixed-effects meta-analysis. We performed several
sensitivity analyses (Supplementary methods). The I2 statistic was
calculated to assess the heterogeneity21 and the p-value for
intercept in MR-Egger was used to assess the directional
pleiotropy.22 Pleiotropic associations of the used SNPs with other
traits were searched in PhenoScanner V2 (Supplementary
Table 4).23 We scaled odds ratios (ORs) and corresponding 95%
confidence intervals (CIs) to one standard deviation (SD) increase
in serum folate, vitamin B6 and vitamin B12 concentrations. The
Bonferroni method was used to correct for multiple testing, and
associations with p-values < 0.008 (p= 0.05/6 outcomes) were
regarded significant. All analyses were two-sided and performed
using the mrrobust package24 in Stata/SE 15.0 and TwoSam-
pleMR25 in R Software 3.6.0.
RESULTS
Associations for positive controls are presented in Supplementary
results and Supplementary Figs. 1, 2. Genetically predicted
circulating concentrations of folate and vitamin B6 were not
associated with risk of overall cancer, overall digestive system
cancer or oesophageal, gastric, colorectal or pancreatic cancer in
either UK Biobank or FinnGen (Figs. 1 and 2). Genetically predicted
serum concentrations of vitamin B12 were associated with overall
digestive system cancer risk in UK Biobank (ORSD 1.12; 95% CI,
1.04, 1.21, p= 0.003) and in the meta-analysis (ORSD 1.10; 95% CI,
1.03, 1.17, p= 0.007) after correction for multiple testing (Fig. 3).
Genetically predicted high serum vitamin B12 was associated with
an elevated risk of colorectal cancer in UK Biobank (ORSD 1.16;
95% CI, 1.06, 1.26, p= 0.001) and both the direction and
magnitude of the association remained in FinnGen (ORSD 1.19;
95% CI, 0.99, 1.43, p= 0.071). The combined ORSD of colorectal
cancer was 1.16 (95% CI, 1.08, 1.25, p < 0.001) (Fig. 3). The
associations of vitamin B12 with overall digestive system cancer
and colorectal cancer were directionally consistent in sensitivity
analyses (Table 1). We did not detect any SNPs driving the
associations of vitamin B12 with overall digestive system cancer or
colorectal cancer (Supplementary Fig. 3). Genetically predicted
serum vitamin B12 was not associated with overall cancer, or
oesophageal, gastric or pancreatic cancer risk (Fig. 3).
DISCUSSION
The present MR study validated genetic instruments for folate and
vitamin B12 using pernicious anaemia (for folate and vitamin B12)
and mean corpuscular volume (for folate) as positive control
outcomes and found that genetically predicted high concentra-
tions of serum vitamin B12 were associated with an increased risk
of overall digestive system cancer and colorectal cancer, but not
overall cancer or oesophageal, gastric or pancreatic cancer.
Genetically predicted serum folate and vitamin B6 concentrations
were not significantly associated with overall cancer or digestive
system cancers.
A pan-carcinogenic effect of high vitamin b12 was not found in
our study, which is consistent with previous RCTs focusing on
effects of administration of folic acid, vitamin B6 and vitamin B12
altogether.26–28 Nevertheless, a 21% higher risk of any cancer was
previously observed with co-supplementation of folate and
vitamin B12, when compared to placebo, after a median
39 months of treatment and an additional 38 months of post-
trial observational follow-up in another RCT.29 Even though the
influence of reverse causality is minimal in the RCT design, this
positive finding might be related to an altered vitamin B12
metabolism caused by carcinogenesis prior to clinical cancer
diagnosis.7,8
Data on vitamin B12 supplementation and gastrointestinal
cancer are scarce and results on vitamin B12 in relation to
colorectal cancer risk in observational studies are conflicting.9,30
One clinical trial reported an increased risk of colorectal cancer
after combined folate and vitamin B12 supplementations,3 which
may be considered support for our findings of positive
associations of genetically predicted vitamin B12 with the
digestive system and colorectal cancer. Furthermore, a previous
MR study revealed a possible association between serum vitamin
B12 and colorectal cancer albeit with concerns on potential
pleiotropy.31 Our study confirmed this association in two
independent populations (not included in previous MR study)
and a series of statistical models minimising influence from
pleiotropy. Given that colorectal cancer makes up a large
proportion of digestive system cancer in UK Biobank it is possible
that the observed association between serum vitamin B12 and
digestive system cancer might be driven solely by its effect on
colorectal cancer.
Rich sources of vitamin B12 include meat, which has previously
been strongly associated with colorectal cancer risk and may
therefore offer a mechanistic explanation for our findings.32 On a
cellular level, vitamin B12 has a vital role in one-carbon
metabolism that influences DNA synthesis, methylation as well
as redox and reductive metabolism. Thus, vitamin B12 may
influence pathways enhancing the proliferation of cancerous
cells.33 It is relevant that the colorectal mucosa is the tissue with
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the highest turnover and is therefore particularly sensitive to
nutrients such as B vitamins, which affect this process. A recent
study demonstrated a higher serum B12 was associated with
tumour-specific hypomethylation in CRC patients, suggestive of
B12-driving epigenetic alterations leading to carcinogenesis.34
Also, of relevance, is that vitamin b12 can be produced by the gut
microbiome and that competition of b12 may affect the gut
microbiome, which offers a further putative mechanistic link with
colorectal cancer.35 A possible carcinogenic effect of high serum
vitamin B12 status has previously been observed in lung cancer36
and possibly epithelial ovarian cancer,37 but not in breast cancer.38
Furthermore, a recent MR study revealed a positive association
between genetically predicted high serum vitamin B12 concen-
trations and risk of inflammatory bowel disease, especially Crohn’s
disease.39 This may be of relevance as patients diagnosed with
inflammatory bowel disease have an increased risk of developing
colorectal cancer.40
Epidemiological data on folate (or folic acid) in relation to
cancer are conflicting. Two meta-analyses based on RCTs found an
increase in the frequency of overall cancer in the folic acid
supplementation group compared to controls.41,42 A borderline
increased overall cancer incidence was observed in a subsequent
meta-analysis of RCTs including 50,000 individuals, although this
finding was compatible with a chance finding as the risk did not
increase with duration of treatment or a daily dose of folic acid.43
Another meta-analysis including 13 trials showed no association
between folate intake and cancer risk,1 consistent with our
finding. With regard to colorectal cancer specifically, an inverse
association with total folate intake was observed in observational
studies,2 although evidence from RCTs does not support an
Cancer & data source OR (95% CI) P-value
0.94 (0.84, 1.04) 0.221
0.99 (0.82, 1.19) 0.882
1.10 (0.85, 1.44) 0.466
0.83 (0.53, 1.30) 0.413
1.32 (0.61, 2.89) 0.481
0.75 (0.10, 5.86) 0.787
1.39 (0.59, 3.31) 0.454
0.50 (0.14, 1.79) 0.285
0.88 (0.49, 1.60) 0.683
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Fig. 1 Associations of genetically predicted higher folate concentrations with cancer. CI indicates confidence interval, OR odds ratio, UKBB
UK Biobank. Estimates were derived from the inverse-variance weighed method with random effects.
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association between folate supplementation and colorectal cancer
risk,2 which is in line with this MR study’s finding.
Dietary vitamin B6 intake showed inverse associations with any
cancer, overall gastrointestinal cancer and oesophageal, gastric,
colorectal44 and pancreatic cancers in meta-analyses of observa-
tional studies.6 However, several RCTs did not detect such
associations.6,26–28 This discrepancy might be related to cancer-
protective confounding effects from foods rich in vitamin B6, such
as whole grains.45 Our study found null associations of vitamin B6
concentrations proxied by a single genetic variant with cancer risk
and thus had offers limited support of any potential application of
vitamin B6 in cancer prevention. We cannot rule out weak
associations of vitamin B6 given small numbers of cases for some
certain site-specific cancer and the use of only one variant, which
explains a relatively low variance in vitamin b6 levels.
There are several strengths and limitations of the present study.
The major strength is the MR design that reinforces the causal
inference. In addition, we examined the associations in two
independent populations and the consistency of results makes our
findings robust. The combination of two independent data also
increases our sample size, thereby enhancing the power to detect
associations. However, the study may still overlook associations for
certain site-specific cancers due to a small number of cases even
after the combination of datasets, especially for folate and vitamin
B6 with small variance explained by genetic instruments. Another
strength of the present study is that most SNPs used as proxies for
B vitamin concentrations are located in genes with known
functions related to folate, vitamin B6 and vitamin B12 and their
corresponding metabolic pathways.46 For folate and vitamin B12,
we validated the genetic instruments using positive controls. The

























1.00 (0.94, 1.07) 0.942
1.06 (0.95, 1.18) 0.333
1.02 (0.96, 1.08) 0.581
0.20 0.50 1.0 2.0 5.0
OR (95% CI)
1.03 (0.87, 1.21) 0.755
0.95 (0.73, 1.23) 0.680
1.00 (0.87, 1.15) 0.962
0.95 (0.59, 1.53) 0.839
0.97 (0.29, 3.21) 0.956
0.95 (0.61, 1.48) 0.835
0.76 (0.45, 1.29) 0.315
1.22 (0.58, 2.57) 0.605
0.89 (0.58, 1.37) 0.603
1.03 (0.84, 1.26) 0.782
0.85 (0.60, 1.20) 0.347
0.98 (0.82, 1.17) 0.819
1.07 (0.72, 1.6) 0.738
0.92 (0.44, 1.92) 0.826
1.04 (0.73, 1.47) 0.849
Fig. 2 Associations of genetically predicted higher vitamin B6 concentrations with cancer. CI indicates confidence interval, OR odds ratio,
UKBB UK Biobank. Estimates were derived from the inverse-variance weighed method with random effects.
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results of pleiotropic effect assessment and sensitivity analyses
further confirm that our findings are less likely to be biased by
pleiotropy. However, caution is required in interpreting the
positive association between vitamin B12 and colorectal cancer
in the absence of biological mechanistic evidence. Lastly, the
population analyzed was confined to European individuals and
thus population stratification bias was diminished.
This study also has important limitations. The population
confinement to individuals of European descent limits the
generalisability of our findings to other populations. Another
limitation is that we cannot assess the gene-environment
interaction using summary-level data. In this regard, some
observational studies have found that the association of folate
and vitamin B6 with cancer risk is modified by the intake of
alcohol,47–50 which may interfere with the intestinal absorption
and metabolism of these nutrients. An additional limitation is that
our results for vitamin B6 were based on a single genetic variant
identified in a GWAS of an Italian population and we were unable
to validate that this variant is associated with vitamin B6
concentrations in the UK and Finnish populations. The analyses
of folate and vitamin B6 were based on few SNPs, and therefore
sensitivity analyses could not be performed. The associations of
genetically predicted vitamin B12 with colorectal cancer and
overall digestive system cancer in the sensitivity analyses were
directionally consistent with the associations from the main
analysis albeit nonsignificant, which might be caused by
inadequate power.51 Further studies with larger power are needed
to verify our findings.
In conclusion, the present study found that genetically
predicted lifelong high serum vitamin B12 concentrations were
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1.13 (0.56, 2.29) 0.727
1.15 (0.95, 1.38) 0.157
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Fig. 3 Associations of genetically predicted higher vitamin B12 concentrations with cancer. CI indicates confidence interval, OR odds ratio,
UKBB UK Biobank. Estimates were derived from the inverse-variance weighed method with random effects.
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associated with an increased risk of colorectal cancer. Further
evidence is needed to assess the safety of wide use of vitamin
B12 supplementation with respect to colorectal cancer
development.
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